AXON Axon Enterprise Inc

BASEL, Switzerland, Feb. 27, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at three investor conferences:

• March 6 at 3:20 p.m. ET at the Cowen and Company 37th Annual Healthcare Conference
• March 14 at 10:45 a.m. ET at the Barclays Global Healthcare Conference
• March 22 at 3:55 p.m. ET at the Oppenheimer 27th Annual Healthcare Conference

A simultaneous webcast will be available for each conference in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following each conference.

About Axovant Sciences 
Axovant Sciences is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-upcoming-investor-conferences-300414201.html

SOURCE Axovant Sciences